고셰병 치료제 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 치료별, 지역별, 부문별 예측(2023-2030년)

Gaucher Disease Drugs Market Growth & Trends:

The global gaucher disease drugs market size is expected to reach USD 2.03 billion by 2030, expanding at a CAGR of 2.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for the development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost.

Gaucher disease is a genetic metabolic disorder, caused by mutations in GBA gene. People with Gaucher disease produce low glucocerebrosidase (GCase), an enzyme required to degrade glucocerebroside. Excess accumulation of lipids in spleen, liver, kidney, brain, lungs, and bone marrow impedes the normal functioning of the organs.

In spite of being the most prevalent lysosomal storage disorder, Gaucher disease is a rare condition with an average prevalence of 1 in 100,000 individuals. However, certain ethnic races such as Ashkenazi Jews are more susceptible to this disorder. Ashkenazi Jews have an average disease prevalence of 1 in 500 individuals.

Currently, type 1 is the most common form of Gaucher disease. This condition is nonneuronopathic in nature, as it does not affect the central nervous system (CNS). Type 1 GD commanded more than 75.0% of the market in 2017. It is estimated to retain its position through 2025. Type 2 and type 3 are not as common as type 1.

On the basis of treatment, enzyme replacement therapy (ERT) was the leading revenue contributor in the market in 2017. The growth of the segment can be attributed to the strong sales of Cerezyme and Vpriv. However, there has been an increase in inclination towards substrate replacement therapy (SRT), spearheaded by Cerdelga and Zavesca. ERT is mostly indicated for type 1 and type 3 (to address issues unrelated to the CNS), as replacement enzymes cannot penetrate blood brain barrier. Additionally, there is no effective treatment for type 2.

Gaucher Disease Drugs Market Report Highlights:

• Type 2 is the rarest of the three forms of GD, with an average mortality rate of less than two years
• Enzyme replacement therapy dominated the treatment landscape, headed by Sanofi Genzyme's Cerezyme. However, GD treatment is witnessing a shift towards substrate replacement therapy
• The U.S. spearheaded the major markets, in terms of sales as well as disease burden. The country will continue to dominate the market through 2030, on account of widening the patient base and easy accessibility to treatments
• Some of the prominent companies operating in the market are Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Therapy
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Therapy outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Gaucher Disease Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Gaucher Disease Drugs Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Gaucher Disease Drugs: Type Estimates & Trend Analysis

• 4.1. Gaucher Disease Drugs Market: Key Takeaways
• 4.2. Gaucher Disease Drugs Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Type 1
  • 4.3.1. Type 1 market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Type 2
  • 4.4.1. Type 2 market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Type 3
  • 4.5.1. Type 3 market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Gaucher Disease Drugs: Therapy Estimates & Trend Analysis

• 5.1. Gaucher Disease Drugs Market: Key Takeaways
• 5.2. Gaucher Disease Drugs Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Enzyme Replacement Therapy
  • 5.3.1. Enzyme replacement therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Substrate Replacement Therapy
  • 5.4.1. Substrate replacement therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Gaucher Disease Drugs Market: Regional Estimates & Trend Analysis

• 6.1. Regional Outlook
• 6.2. Gaucher Disease Drugs Market by Region: Key Marketplace Takeaway
• 6.3. North America
  • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.3. France
    • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.6. Sweden
    • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.7. Norway
    • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.2. China
    • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.3. India
    • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.5. Thailand
    • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.2. Mexico
    • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.7. MEA
  • 6.7.1. Saudi Arabia
    • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Market Participant Categorization
  • 7.2.1. Sanofi
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Takeda Pharmaceutical Company Limited
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Pfizer Inc
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Johnson & Johnson Services, Inc.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. ERAD Therapeutic
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives